Utilizing Live Cell Imaging for Better Lead Selection of Biologics and Bioconjugates

Abzena is a Contract Design and Manufacturing Organisation (CDMO) focused on the development of complex biologics, including antibody-drug conjugates (ADCs) and bispecific antibodies. Successfully advancing these modalities into the clinic requires a comprehensive evaluation of efficacy, safety, and manufacturability, supported by the right in vitro assay strategy.

You will learn from this webinar:

• Importance of holistic assay strategies for complex biologic development
• Pushing the boundaries of live-cell imaging with the Incucyte®
• Using co-culture and spheroid cultures in the presence and absence of immune cells
• Case study insights for ADC and bispecific programs

Who should attend:

• Biologics discovery and preclinical scientists
• ADC and bispecific antibody researchers
• Assay development and in vitro biology scientists
• R&D professionals involved in lead selection and MoA evaluation
• Scientists from pharma, biotech, and CDMO organizations